Biocon’s arm gets voluntary action indicated classification for Bengaluru facility

27 Nov 2025 Evaluate

U.S. Food and Drug Administration (USFDA) CDER-OC, Office of Manufacturing Quality has classified Biocon’s subsidiary -- Biocon Biologics’ (BBL) Drug Substance facility at Biocon Campus, located in Bengaluru, Karnataka, as Voluntary Action Indicated (VAI).

This relates to the inspection conducted by the agency between August 26 to September 3, 2025, and pertains to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States. Biocon Biologics remains committed to global standards of Quality and Compliance.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

391.45 3.20 (0.82%)
05-Dec-2025 14:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.30
Dr. Reddys Lab 1274.40
Cipla 1525.60
Zydus Lifesciences 933.90
Lupin 2101.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×